公告 Olink Holding AB (publ) ADR|Contract Adjustment

发表于 2024-12-23 00:00   109次浏览

公告 [Amend] Solicitation, recommendation statements

发表于 2024-07-11 09:06   124次浏览

公告 Report of foreign issuer [Rules 13a-16 and 15d-16]

发表于 2024-07-11 08:57   92次浏览

公告 Securities to be offered to employees in employee benefit plans, post-effective

发表于 2024-07-11 08:57   118次浏览

公告 Securities to be offered to employees in employee benefit plans, post-effective

发表于 2024-07-11 08:57   113次浏览

公告 Securities to be offered to employees in employee benefit plans, post-effective

发表于 2024-07-11 08:57   121次浏览

公告 Securities to be offered to employees in employee benefit plans, post-effective

发表于 2024-07-11 08:57   104次浏览

公告 Post-effective Amendment to an automatic shelf registration statement

发表于 2024-07-11 08:57   129次浏览

公告 Notification filed by national security exchange to report the removal from lis

发表于 2024-07-10 22:00   108次浏览

公告 [Amend] Solicitation, recommendation statements

发表于 2024-07-08 21:42   119次浏览

公告 [Amend] Solicitation, recommendation statements

发表于 2024-07-06 05:21   166次浏览

公告 Report of foreign issuer [Rules 13a-16 and 15d-16]

发表于 2024-07-06 05:17   141次浏览

公告 [Amend] Solicitation, recommendation statements

发表于 2024-06-21 09:53   119次浏览

公告 [Amend] Tender offer statement by Third Party

发表于 2024-06-20 22:32   137次浏览

公告 Report of foreign issuer [Rules 13a-16 and 15d-16]

发表于 2024-06-12 17:16   106次浏览

再拓新应用！序祯达完成基于DNBSEQ-T7平台的Olink Explore适配验证

近日，上海序祯达生物科技有限公司（以下简称：序祯达生物）实验室在华大智造DNBSEQ-T7平台上完成了OlinkExploreHT产品的适配验证，实验及测序后的数据经过OlinkProteomics（以下简称：Olink）官方验证，得到了100%样本通过QC的好成绩，标志着Olink蛋白组学与DNBSEQ平台兼容取得了新进展，也意味着DNBSEQ-T7平台成功拓展蛋白组学应用。通过序祯达生物...

公告 [Amend] Tender offer statement by Third Party

发表于 2024-05-15 05:18   212次浏览

公告 Report of foreign issuer [Rules 13a-16 and 15d-16]

发表于 2024-05-13 18:17   238次浏览

公告 [Amend] Solicitation, recommendation statements

发表于 2024-05-02 05:57   356次浏览

公告 Olink Holding AB (publ) ADR|Contract Adjustment

发表于 2024-05-02 00:00   86次浏览